Malignant melanoma: An emerging and preventable medical catastrophe

Mayo Clinic Proceedings

Volumn 72, Issue 6, 1997, Pages 570-574

  Creagan, Edward T ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ANAMNESIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CONFERENCE PAPER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; MELANOMA; METASTASIS POTENTIAL; PROGNOSIS; THORAX RADIOGRAPHY; TREATMENT PLANNING;

EID: 0030843767     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.6.570     Document Type: Conference Paper

References (11)

1. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, O'Fallon J, Novotny P. Utility of follow-up tests for detecting diseaserecurrence of surgically resected primary malignant melanoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995; 14:307
2. Creagan ET, Dalton RJ, Ahmann DL, Jung S-H, Morton RF, Langdon RM Jr, et al. Randomized, surgical adjuvant clinical trial of recombinant Interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776-2783
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17
4. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme [letter]. Lancet 1994; 343:913-914
5. Prescott LM. Adjuvant interferon alfa-2a improves survival in locally advanced melanoma: WHO study. Clin Cancer Lett 1995; 18(No. 6): 1-3
6. Creagan ET. Regional and systemic strategies for metastatic malignant melanoma. Mayo Clin Proc 1989; 64:852-860
7. Creagan ET, Schaid DJ, Ahmann DL, Frytak S. Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. J Invest Dermatol 1990; 95(Suppl):188S-192S
8. Kirkwood JM. Systemic therapy of melanoma. Curr Opin Oncol 1994; 6:204-211
9. Rusthoven J, Quirt I, Iscoe N, McCulloch P, James K, Lohmann R, et al. A randomized, placebo-controlled trial comparing BCNU (B), dacarbazine (D), and cisplatin (P) versus BDP and high-dose tamoxifen in the treatment of metastatic melanoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995; 14:413
10. Creagan ET. Psychosocial issues in oncologic practice. Mayo Clin Proc 1993 ; 68:161 -167
11. Lickiss JN. Palliative care and melanoma: the care of the patient with progressive disease. World J Surg 1992; 16:282-286